scholarly journals Combined assays for serum carcinoembryonic antigen and microRNA-17-3p offer improved diagnostic potential for stage I/II colon cancer

2015 ◽  
Vol 3 (6) ◽  
pp. 1315-1318 ◽  
Author(s):  
JINHAI ZHU ◽  
HUIMING DONG ◽  
QIONG ZHANG ◽  
SHANGWU ZHANG
Keyword(s):  
Colon Cancer ◽  
Carcinoembryonic Antigen ◽  
Stage I ◽  
Diagnostic Potential ◽  
Serum Carcinoembryonic Antigen

Surveillance with Serial Serum Carcinoembryonic Levels Detect Colorectal Cancer Recurrences in Patients who are Initial Nonsecretors

2010 ◽  
Vol 76 (10) ◽  
pp. 1100-1103 ◽  
Author(s):  
Alicia Holt ◽  
Rebecca A. Nelson ◽  
Lily Lai
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Retrospective Review ◽  
Stage I ◽  
Recurrent Colorectal Cancer ◽  
Serum Carcinoembryonic Antigen ◽  
Serial Serum ◽  
Resected Stage ◽  
Initial Resection

Serum carcinoembryonic antigen (CEA) levels, elevated in a subgroup of patients with colorectal cancer (CRC) at presentation, are serially followed as part of recommended surveillance after initial resection. The value of following serial CEA levels in patients who initially present with less than or normal levels of CEA (nonsecretors) is controversial. This study sought to determine the use of follow-up CEA levels in nonsecretors. A retrospective review was performed of patients with resected Stage I, II, and III CRC. We excluded patients who did not have a pretreatment CEA level, at least two follow-up CEA levels, or in whom CEA levels did not normalize after resection. The patients were grouped by initial CEA values: CEA 5 ng/mL or less (nonsecretors) and CEA 5 + ng/mL: (secretors). We identified 186 patients with CRC; 146 were initial nonsecretors. We identified 22 patients with recurrent colorectal cancer; 6 were secretors and 16 patients were nonsecretors. In the secretors group, CEA was elevated with recurrence in four (66%) of the patients. In the nonsecretors, CEA was elevated with recurrence in eight (50%) of the patients. In summary, many recurrences of CRC are marked by an elevation of CEA regardless of whether the patients initially presented as secretors or nonsecretors.

Incorporation of serum carcinoembryonic antigen levels into the prognostic grouping system of colon cancer

2017 ◽  
Vol 32 (6) ◽  
pp. 821-829 ◽  
Author(s):  
Heita Ozawa ◽  
Kenjiro Kotake ◽  
Miki Hosaka ◽  
Akira Hirata ◽  
Yusuke Nakagawa ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Carcinoembryonic Antigen ◽  
Serum Carcinoembryonic Antigen

scholarly journals Superiority of fecal carcinoembryonic antigen as diagnosis marker for adenomatous polyposis coli and asymptomatic colorectal cancer

2021 ◽  
Vol 14 ◽  
pp. 175628482110627
Author(s):  
Linfang Li ◽  
Wenshen Gu ◽  
Xingping Wu ◽  
Yufeng Ao ◽  
Yiling Song ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Adenomatous Polyposis Coli ◽  
Triple Negative ◽  
Double Negative ◽  
Adenomatous Polyposis ◽  
Polyposis Coli ◽  
Intestinal Diseases ◽  
Diagnostic Potential ◽  
Serum Carcinoembryonic Antigen

Background: Non-invasive diagnostic tools of adenomatous polyposis coli (APC) and asymptomatic colorectal cancer (CRC) are urgently needed. Although fecal carcinoembryonic antigen (FCEA) has been documented in some studies, the diagnostic potential for the detection of APC and asymptomatic CRC has not been described yet. Methods: This is a retrospective study. The pre-diagnostic serum carcinoembryonic antigen (SCEA) and fecal occult blood test (FOBT) levels were retrospectively analyzed in 212 patients with intestinal diseases group (IDG) and 224 controls. The levels of FCEA across all the studied groups were measured using electronic chemiluminescence immunoassay (ECLIA), and their sensitivity and specificity were used to evaluate their diagnostic potential. The individual diagnostic accuracy of the three indices, as well as their combined diagnostic potential, was compared using the receiver operating characteristic (ROC) curve and chi-square test. Results: The FCEA had low sensitivity (50%) and high specificity (93.91%) for the diagnosis of IDG, with the area under the curve (AUC) value of 0.781. The AUC of FCEA was higher than that of SCEA for the diagnosis of APC and CRC in the APC, asymptomatic CRC, and APC + CRC-stage I patients. The AUCs of FCEA were 0.708 and 0.691 for the ‘double-negative patients’ and ‘triple-negative patients’, respectively. In addition, FCEA could diagnose 45.5% of the ‘double-negative’ patients, 43.3% of the asymptomatic patients, and 42.9% of the ‘triple-negative’ patients. The combination of FCEA and FOBT improved the diagnostic value (AUC = 0.916). Conclusion: FCEA has been demonstrated to be a favorable diagnostic marker in intestinal diseases, especially in the APC, asymptomatic CRC, and ‘double-negative’ or ‘triple-negative’ CRC patients.

Association of postoperative serum carcinoembryonic antigen (CEA) with disease-free survival in patients with stage III colon cancer: ACHIEVE phase III randomized clinical trial.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4069-4069
Author(s):  
Masahito Kotaka ◽  
Dai Manaka ◽  
Tetsuya Eto ◽  
Junichi Hasegawa ◽  
Akinori Takagane ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Colon Cancer ◽  
Carcinoembryonic Antigen ◽  
Cox Regression ◽  
Disease Free Survival ◽  
Free Survival ◽  
Cutoff Values ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea ◽  
Disease Free

4069 Background: ACHIEVE, as part of the IDEA collaboration, was a multicenter trial randomizing patients with stage 3 resected colon cancer to either 3 versus 6 months of adjuvant FOLFOX/CAPOX. We previously reported that the hazard ratios (HRs) in disease-free survival (DFS) of 3 versus 6 months duration according to risk stage (low-risk [T1-3 and N1] or high-risk [T4 or N2]) and regimen (FOLFOX or CAPOX) as well as in overall population were consistent with those observed in the whole IDEA. This study aimed to clarify the significance of post-operative serum carcinoembryonic antigen (CEA) on DFS in stage 3 colon cancer. Methods: Eligibility included post-operative serum CEA value of ≤10 ng/ml at registration in the ACHIEVE trial, which enrolled 1313 patients between 2012 and 2014, out of whom 1291 pts were the modified ITT (mITT) population and used in this study. The cutoff values of CEA analyzed for prognostic analyses were the median value (1.8 ng/ml) in the mITT, the upper limit of normal (ULN) level (5.0 ng/ml), and the half of ULN (2.5 ng/ml). The association of post-operative CEA with DFS were measured by Cox regression analyses. Results: Of the 3 cutoff values, the ULN (5.0 ng/ml) was associated with DFS more strongly than the median (1.8 ng/ml) or half of ULN (2.5 ng/ml), with a HR of 1.75 (95%CI, 1.24-2.46) (Table). The 99 patients (7.7%) were identified as the CEA > ULN and 1192 (92.3%) as < ULN. In univariate analysis, regimen (CAPOX or FOLFOX), ECOG PS (0 or 1), T factor (T1-3 or T4), N factor (N1 or N2-3) and CEA ( < ULN or > ULN) were significantly associated with DFS. Multivariate Cox regression identified CEA > ULN as an independent poor risk factor (HR = 1.45; 95%CI, 1.03-2.05). Shorter DFS in patients with CEA > ULN than in those with CEA < ULN was consistently observed in each subgroup of baseline factors, including treatment duration, regimen, age, gender, PS, T-stage, N-stage, no of lymph nodes examined, and tumor location; no interaction was observed between CEA and these factors. Conclusions: Post-operative serum CEA is also a strong prognostic factor for DFS in stage 3 colon cancer. Clinical trial information: 000008543 . [Table: see text]

scholarly journals Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome

JAMA Oncology ◽  
2018 ◽  
Vol 4 (3) ◽  
pp. 309 ◽  
Author(s):  
Tsuyoshi Konishi ◽  
Yoshifumi Shimada ◽  
Meier Hsu ◽  
Lauren Tufts ◽  
Rosa Jimenez-Rodriguez ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Carcinoembryonic Antigen ◽  
Serum Carcinoembryonic Antigen ◽  
Postoperative Serum ◽  
Cancer Outcome
Sign in / Sign up

Export Citation Format

Share Document